MoonLake Immunotherapeutics (id:5274 MLTX)
52.03 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 7:48:46 PM)
Exchange closed, opens in 13 hours 41 minutes
3.91 USD (3.91%)
0.10 USD (0.10%)
6.10 USD (6.10%)
26.47 USD (26.47%)
12.89 USD (12.89%)
412.11 USD (412.11%)
About MoonLake Immunotherapeutics
Market Capitalization 3.31B
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| Headquarters (address) |
Dorfstrasse 29 Zug 6300 Switzerland |
| Phone | 41 415108022 |
| Website | https://www.moonlaketx.com |
| Employees | 50 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MLTX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 37.55 - 64.98 |
| Market Capitalization | 3.31B |
| P/E trailing | -68.25 |
| P/E forward | -19.45 |
| Price/Book | 6.31 |
| Beta | 1.28 |
| EPS | -1.18 |
| EPS Switzerland (ID:153, base:185) | 29.31 |